Publication | Open Access
Tocilizumab in COVID‐19 interstitial pneumonia
18
Citations
15
References
2021
Year
Objective clinical response rate overcame the pre-defined threshold of 30%. Efficacy of tocilizumab to improve respiratory function in patients selected according to our inclusion criteria warrants investigations in randomized trials.
| Year | Citations | |
|---|---|---|
Page 1
Page 1